Aspirin and Mortality from Coronary Bypass Surgery
Indexed incrossrefpubmed
Abstract
Background
There is no therapy known to reduce the risk of complications or death after coronary bypass surgery. Because platelet activation constitutes a pivotal mechanism for injury in patients with atherosclerosis, we assessed whether early treatment with aspirin could improve survival after coronary bypass surgery.
Methods
At 70 centers in 17 countries, we prospectively studied 5065 patients undergoing coronary bypass surgery, of whom 5022 survived the first 48 hours after surgery. We gathered data on 7500 variables per patient and adjudicated outcomes centrally. The primary focus was to discern the relation between early aspirin use and fatal and nonfatal outcomes.
Citation impact
675
total citations
- FWCI
- 19.76
- Percentile
- 100%
- References
- 47
Citations per year
Authors
1Topics & keywords
Topics
Keywords
- Medicine
- Aspirin
- Bypass surgery
- Cardiology
- Surgery
- Internal medicine
- Coronary artery bypass surgery
- Artery
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of Veterans Affairs
- MGMassachusetts General Hospital
- YUYale University
- EUEmory University
- UOUniversity of Washington
- UOUniversity of Rochester
- TJThomas Jefferson University
- UOUniversity of Arkansas for Medical Sciences
- UOUniversity of Ottawa
- THTexas Heart Institute
- YUYork University
- UOUniversity of Alberta
- UHUniversität Heidelberg
- UOUniversity of Toronto
- RFRheinische Friedrich-Wilhelms-Universität Bonn
- JWJulius-Maximilians-Universität Würzburg
- KGKarl-Franzens-Universität Graz
- IDInstitut de Cardiologie de Montréal
- UOUniversity of Texas Health Science Center at San Antonio
- FOFaculty of Medicine Siriraj Hospital, Mahidol University